Completed PHASE3 INTERVENTIONAL NCT00005867

Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma

Phase III Trial Comparing CHOP ot PMitCEBO in Good Risk Patients With Histologically Aggresive Non Hodgkin's Lymphoma

Sponsor: Lymphoma Trials Office

Conditions Lymphoma

Interventions CHOP regimen bleomycin sulfate cyclophosphamide doxorubicin hydrochloride etoposide mitoxantrone hydrochloride prednisolone vincristine sulfate

Updated 6 times since 2017 Last updated: Jun 25, 2013 Started: Jan 31, 1998 Completion: Aug 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00005867, this PHASE3 trial focuses on Lymphoma and remains completed. Sponsored by Lymphoma Trials Office, it has been updated 6 times since 1998, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lymphoma Trials Office

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United Kingdom , Aylesbury-Buckinghamshire, United Kingdom , Banbury, United Kingdom , Bangor, United Kingdom , Basildon, United Kingdom , Belfast, United Kingdom , Birmingham, United Kingdom , Bradford, United Kingdom , Bristol, United Kingdom , Cambridge, United Kingdom and 31 more locations